Milgamma Na (Thiamine Hydrochloride, Pyridoxine Hydrochloride)

Thiamine hydrochloride is converted in cells to thiamine pyrophosphate, the active co‑enzyme form. This co‑enzyme is essential for enzymes that decarboxylate carbohydrates, such as pyruvate dehydrogenase and α‑ketoglutarate dehydrogenase, facilitating the production of ATP and supporting normal nervous system function.

The dose of Milgamma Na is individualized by the prescribing healthcare professional based on the patient’s clinical condition, severity of deficiency, age, weight, renal function, and route of administration. No fixed regimen is provided here; clinicians calculate the appropriate amount and frequency for each case.

Safety data for Milgamma Na in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. The prescribing clinician must evaluate the risk‑benefit profile before initiating therapy in pregnant or nursing women.

To order Milgamma Na, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain where applicable) and any required import documentation.

Milgamma Na contains only thiamine hydrochloride and pyridoxine hydrochloride, whereas many other vitamin B complex injections include additional B‑vitamins such as cyanocobalamin (B12) or riboflavin (B2). Milgamma Na is therefore targeted for conditions specifically related to B1 and B6 deficiencies, offering a focused formulation that may reduce the risk of unnecessary vitamin exposure compared with broader‑spectrum products.

Milgamma Na must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing. Before administration, allow the solution to reach room temperature if required, and do not shake vigorously to prevent degradation of the active ingredients.

Milgamma Na is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) injection. The route, volume, and rate of infusion are determined by the prescribing clinician. Proper aseptic technique and, for IV use, appropriate dilution in compatible fluids are essential to ensure safe delivery.

The most serious adverse events include anaphylactic or severe allergic reactions, sudden hypotension after rapid IV infusion, and rare dermatologic emergencies such as Stevens‑Johnson syndrome. Patients should be monitored during and after administration, and any signs of severe hypersensitivity or cardiovascular instability require immediate medical intervention.

Milgamma Na should be avoided in individuals with a known hypersensitivity to thiamine, pyridoxine, or any excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those receiving medications that may interact significantly with vitamin B metabolism. The decision to withhold therapy rests with the treating clinician.